Erste Asset Management GmbH Takes $10.14 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Erste Asset Management GmbH purchased a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 260,000 shares of the company’s stock, valued at approximately $10,136,000.

Several other large investors also recently bought and sold shares of MIRM. Candriam S.C.A. purchased a new position in Mirum Pharmaceuticals in the 2nd quarter valued at about $17,384,000. Loomis Sayles & Co. L P acquired a new stake in Mirum Pharmaceuticals in the third quarter valued at $19,473,000. Clearbridge Investments LLC lifted its position in shares of Mirum Pharmaceuticals by 165.5% during the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock worth $23,931,000 after purchasing an additional 436,349 shares during the last quarter. PDT Partners LLC lifted its holdings in Mirum Pharmaceuticals by 188.9% during the 3rd quarter. PDT Partners LLC now owns 113,712 shares of the company’s stock worth $4,435,000 after buying an additional 74,349 shares during the last quarter. Finally, HealthInvest Partners AB boosted its holdings in Mirum Pharmaceuticals by 83.9% in the third quarter. HealthInvest Partners AB now owns 138,321 shares of the company’s stock worth $5,395,000 after purchasing an additional 63,121 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MIRM. Leerink Partners raised their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Evercore ISI increased their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Citigroup raised their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $57.73.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00. Following the sale, the senior vice president now directly owns 2,426 shares of the company’s stock, valued at $114,264.60. The trade was a 50.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ MIRM opened at $46.22 on Monday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $48.89. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -22.88 and a beta of 1.16. The business has a fifty day simple moving average of $40.93 and a 200-day simple moving average of $37.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same period in the prior year, the firm earned ($0.57) earnings per share. The business’s quarterly revenue was up 89.4% on a year-over-year basis. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.